TTR

TTR is a homotetrameric transport protein that carries thyroxine (T4) through two binding sites at the center of the dimer-dimer interface and binds retinol-binding protein (holo-RBP) on both faces of the tetramer (PMID:22471981), functioning as a positive regulator of RBP-bound retinol delivery into cells (PMID:8102146, PMID:9260907). The same dimer-dimer interface that forms the T4 sites is the locus of TTR's pathological behavior: amyloid fibril formation proceeds through rate-limiting dissociation of the native tetramer into non-native monomers that assemble into oligomers, protofibrils, and mature deposits (PMID:22471981, PMID:10940233), and destabilizing mutations such as A25T accelerate this cascade in proportion to their loss of tetramer stability (PMID:22091638). This mechanistic link is exploited therapeutically by small-molecule kinetic stabilizers (tafamidis, diflunisal) that occupy the T4 sites at the dimer-dimer interface to block dissociation (PMID:29615436), while stabilizing variants such as T119M and R104H confer intrinsic resistance to dissociation, showing tetramer stability is separable from T4 binding affinity (PMID:10772944). Beyond transport, TTR possesses metal-dependent peptidase activity that cleaves peptides without strict sequence specificity through a metalloprotease mechanism (PMID:23000319), and it modulates amyloid-beta in vivo, with TTR haploinsufficiency accelerating Abeta deposition in an Alzheimer model (PMID:17596449). TTR expression is compartment-specific: neuronal TTR is transcriptionally induced by the stress-responsive factor HSF1 acting directly at promoter heat shock elements, a regulation absent in hepatocytes and cardiomyocytes (PMID:24849358), and choroid plexus-derived CSF TTR is produced independently of hepatic plasma TTR (PMID:27884058).

1. 1987 High

   Establishing the chromosomal locus of human TTR provided the genetic foundation for linking the gene to inherited amyloid disease.

   Evidence somatic cell hybrid analysis and in situ hybridization mapping to 18q11.2-q12.1

   PMID:3028932

   Open questions at the time

   • Localization alone established no protein function or disease mechanism
2. 1993 Medium

   Resolving whether a TTR variant alters T4 handling distinguished concentration effects from intrinsic affinity changes and confirmed TTR's physiological role in RBP transport.

   Evidence serum dialysis, isoelectric focusing, peptide mapping and DNA analysis of Met119 carriers

   PMID:8102146

   Open questions at the time

   • Did not resolve the structural basis of the binding sites
   • Single variant in human carriers
3. 1997 Medium

   Showing TTR enhances cellular retinol uptake from the RBP-TTR complex established TTR as an active facilitator rather than a passive carrier in retinol delivery.

   Evidence primary rat hepatocyte uptake assays with labeled retinol complexes and competition experiments

   PMID:9260907

   Open questions at the time

   • The putative membrane receptor mediating uptake was not identified
   • Demonstrated in rat hepatocytes only
4. 2000 Medium

   Demonstrating that stabilizing variants resist dissociation while differing in T4 affinity showed tetramer stability and ligand binding are mechanistically separable, a key principle for stabilizer design.

   Evidence in vitro dissociation-resistance stability assays and T4 binding studies of T119M and R104H

   PMID:10772944

   Open questions at the time

   • Single-lab in vitro study
   • Did not establish in vivo protection from amyloidosis
5. 2011 High

   Linking the thermodynamic instability of A25T-TTR to fibril formation and CSF co-aggregation defined how destabilizing mutations drive the amyloid cascade and engage partner proteins.

   Evidence X-ray crystallography, pressure-induced dissociation, in vitro fibrillation, and proteomics of co-aggregates

   PMID:22091638

   Open questions at the time

   • Functional consequence of co-aggregation with the 19 partner proteins not established
   • Relevance of CSF co-aggregation to in vivo disease unresolved
6. 2012 High

   Crystallographic resolution of the T4 and holo-RBP binding sites and consolidation of the dissociation-driven amyloid model unified TTR's transport and pathological mechanisms onto the dimer-dimer interface.

   Evidence synthesis of nearly 200 X-ray crystal structures of TTR and complexes, plus in vitro aggregation and biophysical characterization

   PMID:10940233 PMID:22471981

   Open questions at the time

   • Structures do not capture transient oligomeric/protofibril intermediates
   • Did not address tissue-specific regulation
7. 2012 Medium

   Identifying intrinsic metal-dependent peptidase activity revealed a catalytic function for TTR beyond ligand transport.

   Evidence FRET peptide cleavage assays, metal chelator inhibition, and pH/proton-inventory mechanistic profiling

   PMID:23000319

   Open questions at the time

   • Physiological substrates not identified
   • Catalytic metal and active-site residues not definitively assigned
8. 2007 High

   Genetic ablation experiments established that TTR modulates Abeta deposition in vivo, extending its role to Alzheimer-relevant proteostasis.

   Evidence TTR hemizygous knockout crossed with APPswe/PS1deltaE9 mice, biochemical Abeta quantification and histology

   PMID:17596449

   Open questions at the time

   • Molecular mechanism by which TTR limits Abeta deposition not resolved
   • Relationship to TTR's own aggregation propensity unclear
9. 2013 Medium

   Demonstrating that SAP binds early TTR aggregates and rescues toxicity in vitro and in flies identified a protective modifier of TTR aggregate toxicity.

   Evidence in vitro binding and cell viability assays plus a Drosophila TTR amyloidosis model with retinal histology

   PMID:23390551

   Open questions at the time

   • Mechanism of SAP-mediated protection not defined
   • Human relevance of the fly model phenotype not established
10. 2014 High

    Identifying HSF1 as a direct, neuron-specific transcriptional activator of TTR explained compartment-restricted TTR induction under stress.

    Evidence ChIP for HSF1 occupancy of TTR promoter heat shock elements with HSF1 gain/loss-of-function across neuronal cells and APP23 mice

    PMID:24849358

    Open questions at the time

    • Upstream signals activating HSF1 at the TTR promoter not defined
    • Functional outcome of elevated neuronal TTR not quantified
11. 2016 Medium

    Linking TTR V30M aggregates to selective autophagy impairment defined a cellular pathology that is pharmacologically reversible.

    Evidence p62 accumulation and LC3 turnover assays in cells plus TUDCA/curcumin treatment in V30M transgenic mice

    PMID:27382986

    Open questions at the time

    • Molecular step in autophagy targeted by aggregates not pinpointed
    • Single-lab study
12. 2018 Medium

    Connecting interface-binding kinetic stabilizers to improved clinical outcomes validated the dissociation model as a therapeutic target in cardiac amyloidosis.

    Evidence structural mechanism of tafamidis/diflunisal at the dimer-dimer interface combined with a retrospective clinical cohort

    PMID:29615436

    Open questions at the time

    • Clinical evidence is retrospective single-center
    • Not a prospective mechanistic intervention study
13. 2019 Medium

    Systemic TTR knockdown that cleared peripheral deposits but left CSF TTR unchanged established that choroid plexus CSF TTR is produced independently of hepatic plasma TTR.

    Evidence systemic TTR siRNA in V30M transgenic mice with immunohistochemistry and blood/CSF TTR measurement

    PMID:27884058

    Open questions at the time

    • Did not establish whether CSF TTR contributes to or protects against CNS amyloid
    • Single transgenic model

• The physiological substrates of TTR's metalloprotease activity and the molecular mechanism by which TTR limits Abeta and engages aggregate-modifying partners remain unresolved.
• No endogenous peptidase substrate identified
• Mechanism of TTR-Abeta interaction in vivo not defined
• Receptor mediating RBP-TTR retinol uptake unidentified